Browse > Article

The Role Of Tumor Marker CA 15-3 in Detection of Breast Cancer Relapse After Curative Mastectomy  

Hyun, In-Young (Department of Nuclear Medicine, Inha University College of Medicine)
Kim, In-Ho (Department of Internal Medicine, Inha University College of Medicine)
Lee, Moon-Hee (Department of Internal Medicine, Inha University College of Medicine)
Kim, Chul-Soo (Department of Internal Medicine, Inha University College of Medicine)
Publication Information
The Korean Journal of Nuclear Medicine / v.38, no.4, 2004 , pp. 311-317 More about this Journal
Abstract
Purpose: The purpose of this study was to determine the utility of tumor marker CA 15-3 in the following: the diagnosis of breast cancer relapse after curative mastectomy, and the differentiation or the value of tumor marker by site of metastases. Materials and Methods: Two hundred two patients (median age 48 years) with breast cancer included in the follow-up after curative mastectomy. The tumor marker CA 15-3 was determined by IRMA (CIS BIO INTERNATIONAL, France). Test values > 30 U/ml were considered elevated (positive). Results: Among 202 patients, recurrent diseases were found in 16 patients. CA 15-3 was elevated in 5 of 16 patients with recurrences. There was no false-positive patient who had elevated CA 15-3. Sensitivity and specificity of CA 15-3 for detection of breast cancer recurrence were 31%, and 100%. CA 15-3 was elevated in all of the 4 patients with liver metastases. CA 15-3 was elevated in none of the patients who relapsed with metastasis to bone-only or contralateral breast-only. Conclusion: The tumor marker CA 15-3 in the detection of breast cancer relapse after curative mastectomy is specific, but not sensitive. However, it is useful to rule out liver metastases of breast cancer, which indicates bad prognosis.
Keywords
breast cancer; CA 15-3; follow-up; relapse; tumor marker;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Hayes DF, Zurawski NR, Kufe DW. Comparison of circulating CA 15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clinic Oncol 1986;4:1542-50   DOI
2 ASCO Special Article. Recommended breast cancer surveillance guidelines. American Society of Clinical Oncology. J Clin Oncol 1997;15:2149-56
3 Linsley PS, Ochs V, Laska S, Horn D, Ring DB, Frankel AE, et al. Elevated levels of a high molecular weight antigen detected by antibody W1 in sera from breast cancer patients. Cancer Res 1986;46:5444-50   PUBMED
4 Kim H, Le YH. CA 15-3 in patients with primary and recurrent breast cancer. J Korean Surg Soc 1995;50:36-41
5 Kokko R, Holli K, Hakama M. Ca 15-3 in the follow-up of localized breast cancer: a prospective study. Eur J Cancer 2002;38:1189-93   DOI   ScienceOn
6 Safi F, Kohler I, Rottinger E, Suhr P, Beger HG. Comparison of CA 15-3 and CEA in diagnosis and monitoring of breast cancer. Int J Biol Markers 1989;4:207-214   PUBMED
7 Krengli M, Pastore G, Maffei S. The importance of the follow-up in patients operated on for breast cancer. A retrospective analysis of 2482 cases. Minerva Med 1993;84:409-15
8 Wojtacki J, Kruszewski WJ, Sliwinska M, Kruszewska E, Hajdukiewicz W, Sliwinski W, et al. Elevation of serum CA 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases. Przegl Lek 2001;58:498-503   PUBMED
9 ASCO Special Article. Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1865-78
10 Moon SD, Jung SS, Kim IC, Lee DS. Comparison of CA 15-3 with CEA as tumor marker of breast cander. J of Korean Cancer Assoc 1992;24:829-33
11 Cheung KL. Editorial comment on 'Serum markers in breast cancer management' Eur J Cancer 2002;38:1165-6
12 O'Rourke TJ: Tumor markers. In; Calabresi P, Schein PS, et al. Medical oncology: basic principles and clinical management of cancer, 2nd ed., pp 163-172, New York, Mcgraw-Hill, inc., 1993
13 Thompson CH, Jones SL, Whitehead RH, McKenzie IF. A human breast tissue-associated antigen detected by a monoclonal antibody. J Natl Cancer Inst 1983;70:409-19   PUBMED
14 Gion M, Boracchi P, Dittadi R, Biganzoli E, Peloso L, Mione R, et al. Prognostic role of serum CA 15.3 in 362 node-negative breast cancers. An old player for a new game. Eur J Cancer 2002;38:1181-8
15 Ministry of Health and Welfare, Republic of Korea Annual Report of Cancer Registry Programme in the Republic of Korea. (2000.1.1-2000.12.31), 2002
16 Jung JH, Park HY, Lee YH. Clinical value of CEA, CA 15-3 and TPS in breast cancer. J Korean Breast Cancer Soc 2001;4:136-43   DOI
17 Kim S-H. Chemotherapy of breast cancer. Kor J Med 2000;58:497-509
18 ASCO Special Article. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1996;14:2843-77   DOI
19 Kim HK, Heo DS, BangY-J, Kim NK. Pattern of recurrence of breast cancer in Korean female patients. J of Korean Cancer Assoc 1999;31:509-16
20 Buffaz P-D, Gauchez A-S, Caravel J-P, Vuillez J-P, Cura C, Agnius-Delord C, et al. Can tumour marker assays be a guide in the prescription of bone scan for breast and lung cancers? Eur J Nucl Med 1999;26:8-11
21 Fisher B, Slack N, Katrych D, Wolmark N: Ten years follow-up results of patients with carcinoma of the breast in a cooperative trial evaluation surgical adjuvant chemotherapy. Surg Gynecol Obstet 1975;140:528-34   PUBMED